Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study

被引:28
作者
Keegan, Theresa H. M. [1 ]
McClure, Laura A.
Foran, James M.
Clarke, Christina A.
机构
[1] No Calif Canc Ctr, Fremont, CA 94538 USA
关键词
NON-HODGKINS-LYMPHOMA; CANCER SURVIVAL; BREAST-CANCER; UNITED-STATES; RITUXIMAB; REGISTRY; THERAPY; OUTCOMES; CLASSIFICATION; SURVEILLANCE;
D O I
10.1200/JCO.2008.18.8052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose A recent report suggested improvements in survival after follicular lymphoma (FL), but not for all racial/ethnic groups. To better understand the reasons for these FL survival differences, we examined the joint influences of diagnostic period, race/ethnicity, and neighborhood socioeconomic status (SES) on survival in a large population-based case series. Methods All patients (n = 15,937) diagnosed with FL between 1988 and 2005 in California were observed for vital status through November 2007. Overall and FL-specific survival were analyzed with Kaplan-Meier and Cox proportional hazards regression. Neighborhood SES was assigned from United States Census data using residence at diagnosis. Results Overall and FL-specific survival improved 22% and 37%, respectively, from 1988 to 1997 to 1998 to 2005, and were observed in all racial/ethnic groups. Asian/Pacific Islanders had better survival than non-Hispanic white, Hispanic, and black patients who had similar outcomes. Lower neighborhood SES was associated with worse survival in patients across all stages of disease (P for trend <.01). Patients with the lowest SES quintile had a 49% increased risk of death from all causes (hazard ratio [HR] = 1.49, 95% CI, 1.30 to 1.72) and 31% increased risk of death from FL (HR = 1.31; 95% CI, 1.06 to 1.60) than patients with the highest SES. Conclusion Evolving therapies have likely led to improvements in survival after FL. Although improvements have occurred within all racial/ethnic groups, lower neighborhood SES was significantly associated with substantially poorer survival. J Clin Oncol 27: 3044-3051. (C) 2009 by American Society of Clinical Oncology
引用
收藏
页码:3044 / 3051
页数:8
相关论文
共 43 条
[1]  
Ahluwalia Indu B, 2003, MMWR Surveill Summ, V52, P1
[2]  
[Anonymous], CLIN PRACT GUID ONC
[3]   Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment [J].
Arcaini, L ;
Colombo, N ;
Passamonti, F ;
Burcheri, S ;
Orlandi, E ;
Brusamolino, E ;
Della Porta, M ;
Rumi, E ;
Montanari, F ;
Pascutto, C ;
Paulli, M ;
Lazzarino, M .
LEUKEMIA RESEARCH, 2006, 30 (03) :277-282
[4]   Associations between community income and cancer survival in Ontario, Canada, and the United States [J].
Boyd, C ;
Zhang-Salomons, JY ;
Groome, PA ;
Mackillop, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2244-2255
[5]   SOCIOECONOMIC-STATUS AND CANCER SURVIVAL [J].
CELLA, DF ;
ORAV, EJ ;
KORNBLITH, AB ;
HOLLAND, JC ;
SILBERFARB, PM ;
LEE, KW ;
COMIS, RL ;
PERRY, M ;
COOPER, R ;
MAURER, LH ;
HOTH, DF ;
PERLOFF, M ;
BLOOMFIELD, CD ;
MCINTYRE, OR ;
LEONE, L ;
LESNICK, G ;
NISSEN, N ;
GLICKSMAN, A ;
HENDERSON, E ;
BARCOS, M ;
CRICHLOW, R ;
FAULKNER, CS ;
EATON, W ;
NORTH, W ;
SCHEIN, PS ;
CHU, F ;
KING, G ;
CHAHINIAN, AP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) :1500-1509
[6]  
Chan WC, 1997, BLOOD, V89, P3909
[7]   INFECTIOUS AND IMMUNOSUPPRESSIVE COMPLICATIONS OF PURINE ANALOG THERAPY [J].
CHESON, BD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2431-2448
[8]   Staging and Evaluation of the Patient with Lymphoma [J].
Cheson, Bruce D. .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2008, 22 (05) :825-+
[9]   Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK [J].
Cheung, CW ;
Burton, C ;
Smith, P ;
Linch, DC ;
Hoskin, PJ ;
Ardeshna, KM .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) :193-200
[10]   Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study [J].
Clarke, CA ;
Undurraga, DM ;
Harasty, PJ ;
Glaser, SL ;
Morton, LM ;
Holly, EA .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (04) :630-638